Abstract:Introduction Gastrointestinal stromal tumors (GISTs) are neoplasms originating from the interstitial cells of Cajal, pacemaker cells responsible for intestinal motility. Patients with locally advanced GISTs and those with borderline resections due to the proximity of vital anatomical structures, which could result in unacceptable post-surgical morbidity, require special therapeutic consideration. Imatinib, a tyrosine kinase inhibitor, has demonstrated significant success in the non-surgical management of metastatic GIST, and its favorable impact on overall survival in the adjuvant setting makes it logical to speculate on the benefit it could provide as a neoadjuvant medication in patients with locally advanced disease. Methods Patients aged 18-90 years with a diagnosis of GIST confirmed by immunohistochemistry (CD117 positivity) who were treated at the Oncology Hospital of Centro Médico Nacional Siglo XXI in Mexico City from January 2012 to December 2016 were included in the study. It is a retrospective study with a duration of four years. Clinical data were collected from the medical records, which included sex, age, tumor location, initial resectability, reason for unresectability, initial tumor size, and mitotic rate. In the case of unresectable disease, patients who were evaluated by medical oncology and who had received treatment with 400 mg of imatinib daily were evaluated. Results A total of 312 patients diagnosed with GIST were analyzed. One hundred thirty-one were men (42%) with a mean age of 57 years, and 181 were women (58%) with a mean age of 59 years. The most frequent anatomical location was the stomach (n=185, 59.2%). At the time of diagnosis, 210 patients (67.3%) presented with resectable disease, while n=102 patients (32.7%) had unresectable disease. A total of 102 patients with unresectable disease received therapy with 400 mg of imatinib per day. Sixteen patients (15.7%) presented a reduction in tumor dimensions and underwent surgery. Conclusion The study highlights the importance of complete surgical resection and the potential benefit of neoadjuvant imatinib therapy in converting unresectable to resectable disease. The results suggest that imatinib can be effective in converting unresectable GISTs to resectable ones, allowing for a complete resection to be performed and obtaining an R0 resection in 93.7% of these cases.

Pathological Complete Response After Neoadjuvant Imatinib in a Recurrent Duodenal Gastrointestinal Stromal Tumor (GIST)

Surgical Management and Outcomes of Duodenal Gastrointestinal Stromal Tumors.

Resection of GIST in the Duodenum and Proximal Jejunum: A Retrospective Analysis of Outcomes

Complete Response of Advanced Rectal Gastrointestinal Stromal Tumors after Imatinib Treatment: A Case Report and Literature Review

Treatment of patients with postoperative recurrent-metastatic gastrointestinal stromal tumor

Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial]

An Unexpected but Interesting Response to a Novel Therapy for Malignant Extragastrointestinal Stromal Tumor of the Mesoileum: a Case Report and Review of the Literature

[Surgical Treatment for Patients with Advanced Gastrointestinal Stromal Tumor after Targeted Therapy].

Preservation of Organ Function in Locally Advanced Non-Metastatic Gastrointestinal Stromal Tumors (GIST) of the Stomach by Neoadjuvant Imatinib Therapy

Cytoreductive Surgery Offers Prognostic Benefits in Metastatic Gastrointestinal Stromal Tumors with Generalized Progression Following Imatinib Therapy: a Single Institute Retrospective Study

Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor.

Imatinib Mesylate Alone for Refractory Advanced Gastrointestinal Stromal Tumor

Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumors

Imatinib Mesylate Neoadjuvant Treatment for Rectal Malignant Gastrointestinal Stromal Tumor.

Duodenal Gastrointestinal Stromal Tumor: Clinicopathological Characteristics, Surgical Outcomes, Long Term Survival and Predictors for Adverse Outcomes.

[Lancet in the Era of Targeted Drug Therapy: the Role of Surgery in the Management of Advanced Gastrointestinal Stromal Tumor].

The Combination Of Neoadjuvant Therapy And Surgical Resection: A Safe And Effective Treatment For Rectal Gastrointestinal Stromal Tumors

Efficacy and Safety of Neoadjuvant Imatinib Therapy for Patients with Locally Advanced Rectal Gastrointestinal Stromal Tumors: A Multi-Center Cohort Study

[New Prospective on Adjuvant Treatment for Gastrointestinal Stromal Tumors].

Preoperative Imatinib Treatment in Patients with Advanced Gastrointestinal Stromal Tumors: Patient Experiences and Systematic Review of 563 Patients

Neoadjuvant Imatinib in Gastrointestinal Stromal Tumors (GIST): The First Analysis of a Mexican Population